BackgroundandaimDrug-elutingbeadtransarterialchemoembolization(DEB-TACE)improvesthesurvivalofpatientswithhepatocellularcarcinoma(HCC),intermediatestage[i.e.BarcelonaClinicLiverCancer-B(BCLC-B)].Theaimofourstudywastoanalysetheoverallsurvival(OS)andprognosticfactorsofpatientswithHCCtreatedwithDEB-TACE.
背景及目的药物洗脱微球经动脉化疗栓塞(DEB-TACE)治疗可提高肝细胞癌(HCC)中期[即巴塞罗那临床肝癌-B期(BCLC-B)]患者的生存。本研究旨在分析DEB-TACE治疗HCC患者的总生存(OS)和预后因素。
PatientsandmethodsPatients’clinicalcoursewasrecordedfromJanuarytoJuly.ThemedianOSwasobtainedbytheKaplan–Meiermethodand北京有好的白癜风医院吗北京白癜风好的医院
本文编辑：佚名
转载请注明出处:网站地址 http://www.towwm.com/kcyfl/10378.html